These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 27245312)
1. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Birendra KC; DiNardo CD Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312 [TBL] [Abstract][Full Text] [Related]
2. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S; JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478 [TBL] [Abstract][Full Text] [Related]
3. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760 [TBL] [Abstract][Full Text] [Related]
4. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. DiNardo CD; Stein EM Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011 [TBL] [Abstract][Full Text] [Related]
5. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. Becker JS; Fathi AT Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690 [TBL] [Abstract][Full Text] [Related]
6. IDH mutations in cancer and progress toward development of targeted therapeutics. Dang L; Yen K; Attar EC Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468 [TBL] [Abstract][Full Text] [Related]
7. IDH1 inhibitor shows promising early results. Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779 [TBL] [Abstract][Full Text] [Related]
8. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670 [TBL] [Abstract][Full Text] [Related]
9. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938 [TBL] [Abstract][Full Text] [Related]